Taletrectinib Approved: ROS1 Lung Cancer Treatment
- The Food and Drug Governance has given the green light to taletrectinib (Ibtrozi, Nuvation Bio Inc.) as a ROS1 tyrosine kinase inhibitor for patients battling locally advanced or...
- The approval for this ROS1 tyrosine kinase inhibitor stems from the TRUST-I and TRUST-II clinical trials.
- The trials revealed that treatment-naive patients achieved an overall response rate (ORR) of 90% in TRUST-I and 85% in TRUST-II.
The FDA approves taletrectinib, a new ROS1 tyrosine kinase inhibitor, offering a potential lifeline for patients grappling with ROS1-positive non-small cell lung cancer. Clinical trials,including TRUST-I and TRUST-II,demonstrated extraordinary response rates,with treatment-naive patients exhibiting up to a 90% overall response. This approval signifies a major advancement in cancer treatment. The recommended dose is 600 mg orally, taken without food restrictions. News Directory 3 provides the latest updates on health breakthroughs. Learn about the duration of response to the treatment, the risks to monitor, and current patient results. Discover what’s next in the fight against lung cancer.
FDA OKs Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
The Food and Drug Governance has given the green light to taletrectinib (Ibtrozi, Nuvation Bio Inc.) as a ROS1 tyrosine kinase inhibitor for patients battling locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
The approval for this ROS1 tyrosine kinase inhibitor stems from the TRUST-I and TRUST-II clinical trials. These open-label studies assessed the drug’s effectiveness in 157 patients who had not previously undergone ROS1 TKI treatment and 113 patients who had.
The trials revealed that treatment-naive patients achieved an overall response rate (ORR) of 90% in TRUST-I and 85% in TRUST-II. For those previously treated, the ORR was 52% in TRUST-I and 62% in TRUST-II.
Among those who responded to the treatment,the duration of response (DOR) lasted 12 months or longer in 72% of treatment-naive patients in TRUST-I and 63% in TRUST-II. In the previously treated group, the DOR lasted at least 6 months in 74% of responders from TRUST-I and 83% from TRUST-II.
the FDA advises a daily oral dose of 600 mg of taletrectinib, ensuring no food consumption two hours before or after administration.
Warnings associated with taletrectinib include potential risks of hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity.